Selvita Valuation
Is SLV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SLV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SLV (PLN70.1) is trading above our estimate of fair value (PLN10.15)
Significantly Below Fair Value: SLV is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SLV?
Other financial metrics that can be useful for relative valuation.
| What is SLV's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | zł1.29b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.1x |
| Enterprise Value/EBITDA | 38.5x |
| PEG Ratio | 1.3x |
Price to Earnings Ratio vs Peers
How does SLV's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 56.4x | ||
INNOVACAP Innova Captab | 32.5x | n/a | ₹26.9b |
SVE Synthaverse | 75.1x | n/a | zł357.5m |
1521 Frontage Holdings | 31.3x | 26.1% | HK$2.6b |
300404 Boji Medical TechnologyLtd | 86.9x | n/a | CN¥2.5b |
SLV Selvita | 18.4x | 13.8% | zł1.3b |
Price-To-Earnings vs Peers: SLV is good value based on its Price-To-Earnings Ratio (18.4x) compared to the peer average (56.4x).
Price to Earnings Ratio vs Industry
How does SLV's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Earnings vs Industry: SLV is good value based on its Price-To-Earnings Ratio (18.4x) compared to the European Life Sciences industry average (34.7x).
Price to Earnings Ratio vs Fair Ratio
What is SLV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.4x |
| Fair PE Ratio | 12x |
Price-To-Earnings vs Fair Ratio: SLV is expensive based on its Price-To-Earnings Ratio (18.4x) compared to the estimated Fair Price-To-Earnings Ratio (12x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | zł70.10 | zł71.28 +1.7% | 7.2% | zł78.70 | zł65.00 | n/a | 5 |
| Apr ’25 | zł66.70 | zł71.58 +7.3% | 7.3% | zł78.70 | zł65.00 | n/a | 5 |
| Mar ’25 | zł59.00 | zł70.18 +18.9% | 10.5% | zł78.70 | zł58.00 | n/a | 5 |
| Feb ’25 | zł59.20 | zł70.18 +18.5% | 10.5% | zł78.70 | zł58.00 | n/a | 5 |
| Jan ’25 | zł58.50 | zł77.94 +33.2% | 26.5% | zł117.50 | zł58.00 | n/a | 5 |
| Dec ’24 | zł63.00 | zł77.94 +23.7% | 26.5% | zł117.50 | zł58.00 | n/a | 5 |
| Nov ’24 | zł62.70 | zł81.74 +30.4% | 22.3% | zł117.50 | zł66.00 | n/a | 5 |
| Oct ’24 | zł62.50 | zł84.70 +35.5% | 20.5% | zł117.50 | zł66.00 | n/a | 5 |
| Sep ’24 | zł67.20 | zł84.90 +26.3% | 20.2% | zł117.50 | zł67.00 | n/a | 5 |
| Aug ’24 | zł74.40 | zł84.90 +14.1% | 20.2% | zł117.50 | zł67.00 | n/a | 5 |
| Jul ’24 | zł67.90 | zł84.90 +25.0% | 20.2% | zł117.50 | zł67.00 | n/a | 5 |
| Jun ’24 | zł68.50 | zł86.10 +25.7% | 18.6% | zł117.50 | zł73.00 | n/a | 5 |
| May ’24 | zł75.00 | zł86.10 +14.8% | 18.6% | zł117.50 | zł73.00 | n/a | 5 |
| Apr ’24 | zł75.00 | zł93.94 +25.3% | 17.7% | zł117.50 | zł73.00 | zł66.70 | 5 |
| Mar ’24 | zł80.90 | zł96.34 +19.1% | 14.7% | zł117.50 | zł77.00 | zł59.00 | 5 |
| Feb ’24 | zł84.90 | zł90.84 +7.0% | 10.3% | zł102.20 | zł77.00 | zł59.20 | 5 |
| Jan ’24 | zł82.90 | zł90.84 +9.6% | 10.3% | zł102.20 | zł77.00 | zł58.50 | 5 |
| Dec ’23 | zł80.80 | zł90.84 +12.4% | 10.3% | zł102.20 | zł77.00 | zł63.00 | 5 |
| Nov ’23 | zł84.50 | zł90.64 +7.3% | 10.5% | zł102.20 | zł77.00 | zł62.70 | 5 |
| Oct ’23 | zł87.10 | zł90.64 +4.1% | 10.5% | zł102.20 | zł77.00 | zł62.50 | 5 |
| Sep ’23 | zł73.70 | zł86.35 +17.2% | 7.6% | zł94.40 | zł77.00 | zł67.20 | 4 |
| Aug ’23 | zł75.20 | zł86.35 +14.8% | 7.6% | zł94.40 | zł77.00 | zł74.40 | 4 |
| Jul ’23 | zł67.00 | zł86.35 +28.9% | 7.6% | zł94.40 | zł77.00 | zł67.90 | 4 |
| Jun ’23 | zł80.80 | zł88.10 +9.0% | 7.5% | zł94.40 | zł77.00 | zł68.50 | 4 |
| May ’23 | zł77.00 | zł88.10 +14.4% | 7.5% | zł94.40 | zł77.00 | zł75.00 | 4 |
| Apr ’23 | zł79.60 | zł88.40 +11.1% | 6.9% | zł94.40 | zł78.20 | zł75.00 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.